Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma

This study tests mezigdomide (CC-92480) — a drug that helps the immune system destroy cancer cells — in people with multiple myeloma (a blood cancer) who have recently received a CAR-T cell therapy called idecabtagene vicleucel (Abecma). The goal is to see if mezigdomide can extend the benefit of CAR-T therapy. **You may be eligible if...** - You are 18 or older with a diagnosis of multiple myeloma - You have received at least 4 prior lines of treatment, including an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody - You received commercially available Abecma (ide-cel) CAR-T therapy and are now between 30 and 90 days post-infusion - Your ECOG performance status is 2 or better **You may NOT be eligible if...** - You are outside the 30–90 day window after your Abecma infusion - You have significant organ failure or uncontrolled infections - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.